Optimal treatment intensification for glycaemic control in patients with type 2 diabetes on two oral agents: real world comparison of GLP-1, OADs and insulin

被引：0
|
作者：
Desouza, C. [1 ]
Kirk, A. Ross [2 ]
Mangla, K. Kant [3 ]
Wolden, M. Lyng [2 ]
Lingvay, I. [4 ]
机构：
[1] Univ Nebraska Med Ctr, Omaha, NE USA
[2] Novo Nordisk AS, Soborg, Denmark
[3] Novo Nordisk Serv Ctr India Pvt Ltd, Bangalore, Karnataka, India
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
596
引用
收藏
页码：S286 / S287
页数：2
相关论文
共 50 条
  • [1] Optimal Treatment Intensification for Glycemic Control in Patients with T2D on Two Oral Agents: Real-World Comparison of GLP-1, OADs, and Insulin
    Desouza, Cyrus
    Kirk, Andreas Ross
    Mangla, Kamal K.
    Wolden, Michael L.
    Lingvay, Ildiko
    DIABETES, 2020, 69
  • [2] Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
    Desouza, Cyrus
    Kirk, Andreas R.
    Mangla, Kamal K.
    Wolden, Michael L.
    Lingvay, Ildiko
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (02)
  • [3] Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
    Lawrence Blonde
    Denis Raccah
    Elisheva Lew
    Juliana Meyers
    Elena Nikonova
    Mayank Ajmera
    Keith L. Davis
    Monica Bertolini
    Bruno Guerci
    Diabetes Therapy, 2018, 9 : 1169 - 1184
  • [4] Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
    Blonde, Lawrence
    Raccah, Denis
    Lew, Elisheva
    Meyers, Juliana
    Nikonova, Elena
    Ajmera, Mayank
    Davis, Keith L.
    Bertolini, Monica
    Guerci, Bruno
    DIABETES THERAPY, 2018, 9 (03) : 1169 - 1184
  • [5] Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting
    Canivell, Silvia
    Mata-Cases, Manel
    Real, Jordi
    Franch-Nadal, Josep
    Vlacho, Bogdan
    Khunti, Kamlesh
    Gratacos, Monica
    Mauricio, Didac
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1373 - 1380
  • [6] Treatment intensification for patients with type 2 diabetes and poor glycaemic control
    Fu, A. Z.
    Sheehan, J. J.
    DIABETES OBESITY & METABOLISM, 2016, 18 (09): : 892 - 898
  • [7] The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes
    van der Klauw, M. M.
    Wolffenbuttel, B. H. R.
    NETHERLANDS JOURNAL OF MEDICINE, 2012, 70 (10): : 436 - 443
  • [8] Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure
    Joubert, M.
    Reznik, Y.
    DIABETES & METABOLISM, 2017, 43 : 2S34 - 2S38
  • [9] Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists
    Charbonnel, Bernard
    DIABETES & METABOLISM, 2015, 41 : S1 - S2
  • [10] The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
    Mads Frederik Rasmussen
    Diabetology International, 2020, 11 : 76 - 86
12345